FDA grants accelerated approval for Astellas, Seattle Genetics' bladder cancer drug - Reuters

(Reuters) - U.S. Food and Drug Administration said on Wednesday it approved Astellas Pharma Inc and Seattle Genetics’ experimental drug to treat advanced bladder cancer, about three months ahead of schedule.

Shares of Seattle Genetics were up 6% at $119.05 after the bell.
================================================== =====
This appears to be one of those ultra-expensive biologic drugs.